Patruno, Cataldo
Fabbrocini, Gabriella
Longo, Giuseppe
Argenziano, Giuseppe
Ferrucci, Silvia Mariel
Stingeni, Luca
Peris, Ketty
Ortoncelli, Michela
Offidani, Annamaria
Amoruso, Giuseppe Fabrizio
Talamonti, Marina
Girolomoni, Giampiero
Grieco, Teresa
Iannone, Michela
Nettis, Eustachio
Foti, Caterina
Rongioletti, Franco
Corazza, Monica
Veneri, Michele Delli
Napolitano, Maddalena http://orcid.org/0000-0003-3309-8190
Angileri, L
Bianchelli, T
Borghi, A
Calabrese, G
Chello, C
Dal Bello, G
Dastoli, S
Ferrillo, M
Galluzzo, M
Gori, N
Hansel, K
Macchia, L
Piras, V
Provenzano, E
Ribero, S
Romanelli, M
Romita, P
,
Article History
First Online: 16 March 2021
Declarations
:
: No funding or sponsorship was received for the conduct of this study or the preparation of this article.
: Cataldo Patruno acted as investigator, speaker, consultant, and advisory board member for AbbVie, Eli Lilly, Novartis, Pfizer, Pierre Fabre, and Sanofi. Gabriella Fabbrocini has been the principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Celgene, Eli-Lilly, Leo Pharma, Novartis, Sanofi, and UCB. Silvia Mariel Ferrucci is a speaker for Novartis and Sanofi Genzyme, is a principal investigator for Eli Lilly, AbbVie, and Sanofi Genzyme, and is an advisory member of Sanofi Genzyme. Luca Stingeni acted as a speaker and board member for Sanofi-Genzyme. Ketty Peris reports grants and personal fees from Almirall and AbbVie, and personal fees from Biogen, Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma, and Janssen, outside the submitted work; Michela Ortoncelli acted as a speaker for AbbVie, Novartis, and Sanofi. Annamaria Offidani acted as an advisory board member, investigator, and speaker for AbbVie, Celgene, Eli Lilly, Galderma, Janssen, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi Genzyme. Giampiero Girolomoni has been a principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Alphasights, Amgen, Biogen, Bristol-Meyers Squibb, Celgene, Celltrion, Eli-Lilly, Genzyme Gerson Lehrman Group, Guidepoint Global, Leo Pharma, Menlo Therapeutics, Novartis, OM Pharma, Pfizer, Regeneron, Samsung, Sandoz, and UCB. Eustachio Nettis in the past 5 years accepted a fee for organizing education for Sanofi. Caterina Foti acted as a speaker for AbbVie, Novartis, and Sanofi. Franco Rongioletti acted as a board advisor member for Sanofi. Maddalena Napolitano acted as a speaker, consultant, and advisory board member for Sanofi, Abbvie, Leo Pharma, and Novartis. Giuseppe Longo, Giuseppe Argenziano, Giuseppe Fabrizio Amoruso<i>,</i> Marina Talamonti, Teresa Grieco, Michela Iannone, Monica Corazza, and Michele Delli Veneri have no conflicts of interest that are directly relevant to the content of this article.
: The Ethics Committee of University of Naples Federico II (Naples, Italy) approved this study (Approval no. CE 116/20).
: Informed consent was obtained from all individual participants involved in the study.
: Consent for publication was obtained from both all individual participants and authors involved in the study.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: CP, GF, and MN designed the study; GA, SF, LS, KP, MO, AO, GFA, MT, TG, MI, FR, and MC contributed to implementation of the research; GL and MDV contributed to the analysis of the results; and CP and MN wrote the manuscript in consultation with GF, GG, and EN.